| | |||||
| lung cancer | |||||
| 新闻 | |||||
| Crizotinib fails to improve disease-free survival in resected early-stage ALK+ non-small cell ... Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) ...
| |||||
| Polysaccharide-Based Fluorescent Cu²⁺-Responsive Nanocarrier for Dendrobium-Induced ... ... Lung Cancer | Non-small cell lung cancer (NSCLC) remains one of the most lethal malignancies worldwide, highlighting the urgent need for the ...
| |||||
| 查看更多结果 | 修改此快讯 | |||||
| 您收到此电子邮件是因为您订阅了Google快讯。 |
以RSS Feed的形式接收此快讯 |
| 发送反馈 |
No comments:
Post a Comment